Free Trial

OKYO Pharma (NASDAQ:OKYO) Trading Up 3.1% - Here's Why

OKYO Pharma logo with Medical background

Key Points

  • The share price of OKYO Pharma rose by 3.1% to $2.35, following a trading session with a volume of 152,538 shares, reflecting a slight decline from its average trading volume.
  • Analyst ratings are mostly positive, with a consensus rating of "Buy" and a target price of $7.00, following upgrades and reiterations from various equity research analysts.
  • Institutional investors have shown increasing interest in OKYO Pharma, with several firms acquiring new stakes in the company throughout 2023.
  • Five stocks to consider instead of OKYO Pharma.

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) shares were up 3.1% on Monday . The stock traded as high as $2.46 and last traded at $2.35. Approximately 152,538 shares changed hands during mid-day trading, a decline of 3% from the average daily volume of 156,773 shares. The stock had previously closed at $2.28.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of OKYO Pharma to a "hold" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $7.00.

Read Our Latest Stock Report on OKYO

OKYO Pharma Price Performance

The business's fifty day moving average price is $2.69 and its two-hundred day moving average price is $1.95.

Hedge Funds Weigh In On OKYO Pharma

Several institutional investors and hedge funds have recently bought and sold shares of OKYO. FNY Investment Advisers LLC acquired a new position in shares of OKYO Pharma during the first quarter worth $25,000. Wealth Enhancement Advisory Services LLC purchased a new position in OKYO Pharma during the 2nd quarter worth $28,000. Finally, Dauntless Investment Group LLC purchased a new position in OKYO Pharma during the 1st quarter worth $2,526,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Company Profile

(Get Free Report)

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

Featured Articles

Should You Invest $1,000 in OKYO Pharma Right Now?

Before you consider OKYO Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.

While OKYO Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.